Hong Kong, Sep 10, 2025– Chime Biologics,a leading global CDMO providing world-class services for biologics developmentand manufacturing, and Arbele, a clinical-stage biopharmaceutical companypioneering immuno-oncology and CDH17-targeted therapies, today announced thesigning of a strategic collaboration agreement during BIOHK 2025.

This collaboration marks a significant step forward inadvancing innovative antibody-drug conjugate (ADC) therapies. Chime Biologicsand Arbele have already launched their first joint project, an IND program fora CDH17-targeted ADC, with plans to pursue a series of additional ADC projectswith the same cell adhesion molecule target CDH17. These will leverage ChimeBiologics’ proprietary high-throughput PCC (Preclinical Candidate) screeningplatform for ADCs, enabling rapid and efficient development of noveltherapeutic candidates.

As part of its long-term strategy, Arbele also announcedplans to expand its footprint in Biolake, Wuhan, China tapping into the region’sfast-growing biopharma R&D and manufacturing talent pools and advancedinfrastructure facilities. This move will accelerate Arbele’sinnovation and pipeline development in China, supporting the company’s missionto bring transformative therapies to patients worldwide.  Under this framework, Arbele is activelyexploring collaborations with leading local hospitals, research institutes, andcompanies to jointly advance innovative research and development.

Quotes:

Jimmy Wei, President of Chime Biologics: “Ourcollaboration with Arbele reflects Chime Biologics’commitment to accelerating the development of breakthrough biologics. Bycombining our advanced technology platforms with Arbele’sinnovative pipeline, we aim to bring life-changing ADC therapies to patientsfaster.”

Dr. John Luk, CEO of Arbele: “Partneringwith Chime Biologics allows us to leverage their world-class CDMO capabilitiesand cutting-edge PCC screening platform. With our planned expansion in Biolake,we are confident this collaboration will drive rapid progress across ourCDH17-targeted programs and beyond.”

The partnership underscores the growing momentum ofcross-border innovation in biopharma, with Hong Kong and Wuhan playing criticalroles in bridging global capital, talent, and technology.

About Chime Biologics

Chime Biologics is a leading global CDMO, focused onensuring our customers' success in delivering innovative biologic medicines topatients across the world. Chime Biologics can support customers end to end,from pre-clinical support and cell line development through to clinical andcommercial manufacturing of drug substance and drug product. Employing ourinnovative and state-of-the-art development and manufacturing capabilities andproven success in supporting our clients with their clinical and commercialauthorizations across the globe, Chime Biologics is a true end-to-end solutionprovider for the biologics industry. With over 500 skilled employees, we sharea common goal to make cutting-edge biomedicines affordable and accessible topatients worldwide, fulfilling our commitment to improving human healthglobally. For more information, please visit www.chimebiologics.com.

About Arbele

Arbele Limited is a clinical-stage biotechnology companydeveloping potential first-in-class and best-in-class immunotherapies fordigestive tract cancers. With strategic focus on CDH17-targetedT-cell engagers and antibody-drug conjugates, we have also established IVD andCDx platforms for screening and detecting CDH17 biomarkers in blood and tissuessamples to facilitate patients’ selection and prognostication. Arbele's missionis to improve survival outcomes for patients with limited treatment options. Learnmore at www.arbelebio.com

鼎康生物与Arbele于BIOHK2025签署战略合作协议

中国香港，2025年9月10日 ——全球领先的生物药开发与生产服务（CDMO）提供商鼎康生物（ChimeBiologics），与处于临床阶段、专注于免疫肿瘤学和靶向治疗的创新型生物制药公司Arbele，于BIOHK 2025期间宣布签署战略合作协议。

本次合作标志着双方在推动创新型抗体偶联药物（ADC）疗法方面迈出了重要一步。鼎康生物与Arbele已正式启动首个联合项目——一项针对CDH17靶点的ADC新药临床试验申请（IND）项目，并计划在同一细胞黏附分子靶点CDH17上持续推进更多ADC合作项目。双方将充分利用鼎康生物自主开发的高通量PCC（候选药物分子）ADC筛选技术平台，以实现新型候选治疗药物的快速高效开发。

作为其长期战略的一部分，Arbele还宣布计划在中国武汉光谷生物城（Biolake）拓展布局，借助该地区快速增长的生物医药研发与生产人才资源以及先进的基础设施条件，加速其创新和研发管线在中国的推进，进一步支持公司“为全球患者带来变革性疗法”的使命。在此框架下，Arbele正积极探索与当地高水平医院、科研院所及企业建立合作，共同推动创新研发。

双方高层致辞：

鼎康生物总裁魏建军 表示：“与Arbele的合作体现了鼎康生物致力于加速突破性生物药开发的承诺。通过将我们先进的技术平台与Arbele的创新研发管线相结合，我们希望能更快地将改变患者生命的ADC疗法带给临床。”

Arbele CEO 陆满晴博士表示：“与鼎康生物的合作让我们能够充分利用其世界一流的CDMO能力和领先的PCC筛选平台。随着我们计划在武汉光谷生物城扩展布局，我们有信心此次合作将大幅加快CDH17靶点相关项目乃至更广泛研发管线的推进。”

此次合作凸显了跨境生物医药创新日益强劲的势头，香港与武汉正在全球资本、人才和技术的对接中发挥着关键作用。

关于鼎康生物

鼎康生物是一家全球领先的CDMO企业，致力于助力客户将创新生物药快速推向全球患者。鼎康生物可为客户提供端到端的综合服务，从临床前研究支持、细胞株开发，到药物原液及制剂的临床和商业化生产。凭借创新、先进的研发与生产能力，以及在支持客户获得全球临床与商业化注册方面的成功经验，鼎康生物已成为生物医药行业真正的一站式解决方案提供商。目前公司拥有500多名专业员工，秉持共同目标——让前沿生物药物更可负担、更易获取，切实履行改善人类健康的承诺。更多信息请访问：www.chimebiologics.com。

关于Arbele

Arbele Limited 是一家处于临床阶段的生物技术公司，致力于开发针对消化道癌症的潜在“首创”及“同类最优”免疫疗法。公司战略重点聚焦于CDH17靶向T细胞接合器 (TCE) 及抗体药物偶联物 (ADC)，并建立了用于筛查和检测血液与组织样本中CDH17生物标志物的体外诊断（IVD）与伴随诊断（CDx）平台，以助力患者筛选及预后评估。Arbele的使命是为治疗选择有限的患者改善生存预后。更多信息请访问：www.arbelebio.com。

‍